2-(4-硝基苯基)乙醇的制备

用2-苯乙醇为原料,经乙酸酯化、混酸硝化、碱性水解得到2-(4-硝基苯基)乙醇,考察了混酸和酯化物的最佳投料比以及反应温度,利用邻、对位终产物的不同熔点确定了最佳结晶温度,总收率79.8%,对位产物含量98.6%.     

4-苄氧基-3-硝基-α-氯代苯乙酮的合成

对羟基苯乙酮经硝化得到4-羟基-3-硝基苯乙酮,再在Na2CO3/KI作用下与氯苄进行O-烷基化反应后进行α-氯代得到4-苄氧基-3-硝基-α-氯代苯乙酮,总收率38%.     

4-苄氧基-3-硝基-α-溴代苯乙酮的合成工艺改进

目的合成4-苄氧基-3-硝基-α-溴代苯乙酮,并进行工艺改进。方法以对羟基苯乙酮为原料,经过硝化、苄基化、溴代三步反应合成得到4-苄氧基-3-硝基-α-溴代苯乙酮,总收率达到45．2％。结果合成产物经熔点、红外光谱、核磁共振谱等分析确定结构正确;与文献报道一致。结论与其他文献方法比较,该法具有操作简单、收率高、污染小、成本低等特点,并可用于工业生产。     

4-苄氧基-3-硝基-α-溴代苯乙酮的合成工艺改进

目的 合成4-苄氧基-3-硝基-α-溴代苯乙酮,并进行工艺改进。     

1-(4-溴苄基)-1-(4-溴苄氧基)脲药代动力学和体外代谢的研究

目的研究1-(4-溴苄基)-1-(4-溴苄氧基)脲(HY-D11)在大鼠体内药代动力学过程及其在大鼠肝脏中的代谢途径。方法建立HY-D11的UV-HPLC生物样本检测方法,灌胃给予HY-D11 66.7 mg·kg-1后,观察HY-D11在大鼠体内的药代动力学过程。研究CYP1A抑制剂(α-萘黄酮)、CYP2B抑制剂(舍曲林)、CYP2C抑制剂(槲皮素)、CYP2D抑制剂(育亨宾)、CYP2E抑制剂(双硫仑)及CYP3A抑制剂(醋竹桃霉素)对HY-D11在大鼠肝微粒体温孵液中代谢的影响。结果 HY-D11在大鼠体内的药代动力学过程符合二室模型。药代动力学参数t max为(3.67±0.52)h,C max为(1.61±0.13)mg·L-1,t1/2z为(3.41±3.91)h,平均滞留时间MRT0-∞为(7.05±0.29)h。HY-D11在大鼠微粒体温孵液中呈现明显的酶促动力学特征。醋竹桃霉素组与对照组相比,对HY-D11代谢有明显抑制作用(P<0.01);而与对照组相比,萘黄酮组、舍曲林组、槲皮素组、育亨宾组、双硫仑组对HY-D11的代谢均无抑制作用(P>0.05)。结论 HYD11在大鼠体内吸收、代谢速度较快,在大鼠体内代谢可能主要由CYP3A介导。     

叔丁基[2-溴-4-(溴甲基)-6-硝基苯基]氨基甲酸酯的合成

以4-甲基-2-硝基苯胺为起始原料,经过两次溴代反应和氨基保护合成了未见文献报道的化合物叔丁基[2-溴-4-(溴甲基)-6-硝基苯基]氨基甲酸酯,总收率60.64%,其结构经LC/MS和1H NMR确证。     

3-甲氧基-4-苄氧基苯甲酸苄酯的合成

3-甲氧基-4-苄氧基苯甲酸苄酯是合成有机药物的一类重要中间体,以香草酸为起始原料,可以有两种合成方法,一种是将香草酸酚羟基苄基化,然后在酸的催化下与苄醇成酯,另一种方法是酚羟基经苄基化,再将羧酸转变为酰氯,最后与苄醇酯化后得产物。反应式如下:     

4′-苄氧基-3′-硝基苯乙酮的合成工艺研究

以对羟基苯乙酮为原料 ,经硝化和苄醚化合成了平喘药福莫特罗的重要中间体 4′ 苄氧基 3′ 硝基苯乙酮 ,反应总收率为 6 9% ,方法简单、可行 ,适于工业化生产。     

N-(4-氯-3-三氟甲基苯基)-N'-(4-溴苯基)脲的合成

4-氯-3-三氟甲基苯胺和三光气在乙酸乙酯中反应制得4-氯-3-三氟甲基苯异氰酸酯,不经分离纯化,直接与对溴苯胺反应制得抗肿瘤药索拉非尼的中间体N-(4-氯-3-三氟甲基苯基)-N'-(4-溴苯基)脲,总收率约75%,纯度99.8%.     

(2R,3S)-2-[(R)-1-[3,5-二(三氟甲基)苯基]乙氧基]-3-(4-氟苯基)吗啉盐酸盐的合成

对甲氧基苯甲醛(3)和2-氨基乙醇进行还原胺化反应得2-(4-甲氧基苄胺基)乙醇(4),4和乙醛酸经成环反应得2-羟基-4-对甲氧基苄基吗啉-3-酮(5),5和三氟乙酐反应得6后与(R)-1-[3,5-二(三氟甲基)苯基]乙醇(7)缩合,再经结晶诱导不对称转化、格氏反应、氢化脱保护及成盐反应制得阿瑞吡坦关键中间体(2R,3S)-2-[(R)-1-[3,5-二(三氟甲基)苯基]乙氧基]-3-(4-氟苯基)吗啉盐酸盐,总收率约18%(以3计)。     

Synthesis and antimicrobial activity of some 1-(2,4-dinitrophenyl)-3-(3-nitrophenyl)-5-(4-substituted phenyl)-4-bromo-2-pyrazolines and 1-(2,4-dinitrophenyl)-3-(3-nitrophenyl)-5-(4-substituted phenyl)-2-pyrazolin-4-ones

A series of 1-(2,4-dinitrophenyl)-3-(3-nitrophenyl)-5-(4-substituted phenyl)-2-pyrazolin-4-ones (4a-e) have been synthesized by the oxidation of 1-(2,4-dinitrophenyl)-3-(3-nitrophenyl)-5-(4-substituted phenyl)-4-bromo-2-pyrazolines (3a-e) with dimethylsulfoxide. The structure has been established on the basis of spectral data (IR,1H NMR). The synthesized compounds have been screened in vitro for their possible antimicrobial activity.     

Calorimetric Determination of the Enantiomeric Purity of (1R,2R)-2-Amino-1-(4-nitrophenyl)-1,3-propanediol

The determination of enantiomeric purity by Differential Scanning Calorimetry (DSC) was applied in the case of (1R,2R)-2-amino-1-(4-nitrophenyl)-1,3-propanediol. In the range of enantiomeric excess (greater than 95%), the direct and indirect methods gave identical results.     

Direct Separation of (1R,2R)-2-Amino-1-(4-nitrophenyl)-1,3-propanediol in a Resolution of its Conglomerate

The conglomerate being more soluble than its enantiomers is the sole racemic modification that can be resolved in a direct way. Some classical cases requiring a single operation are known and they have been defined as the simultaneous and separate crystallization of enantiomers¹⁾. Much better known is the resolution of enantiomers by a sequence of alternate crystallization which takes place in the resolution by entrainment²⁾ also appropriately called “seesaw method”³⁾. (IR,2R)-2-Amino-1-(4-nitrophenyl)-1,3-propanediol. In an Erlenmeyer 250 ml flask with a reflux condenser 4.8 g (0.025 mol) of quinic acid and 10.6 g (0.05 mol) of (1RS,2RS)-2-amino-1-(4-nitrophenyl)-1,3-propanediol were dissolved in 110 ml of methanol by heating at reflux for a few min. The clear solution so obtained was left overnight at room tem. (20–24°C).     

Synthesis of methyl 2, 6-dimethyl-5-(1′, 2′-dioxo-2′-ethoxyethyl)-4-(3′-nitrophenyl)-1,4-dihydropyridine-3-carboxylate

Hantzch’s type reaction of methyl acetopyruvate(2a), methyl 3-aminocrotonate(3) and 3-nitrobenzaldehyde(4) led to dimethyl 3-acetyl-6-methyl-4-(3′-nitrophenyl)-2,5-dicarboxylate(5a) and methyl 2,6-dimethyl-5-(1′, 2′-dioxo-2′-methoxyethyl)-4-(3′-nitrophenyl)-1,4-dihydropyridine-3-carboxylate(6a) in 26.7 and 9.2% yield, respectively. On the other hand, methyl 2,6-dimethyl-4-(3′-nitrophenyl)-1, 4-dihydropyridine 3-carboxylate(9) was acylated by ethyl oxaly chloride to give methyl 2,6-dimethyl-5-(1′,2′-dioxo-2′-ethoxyethyl)-4-(3′-nitrophenyl)-1,4-dihydropyridine-3-carboxylate(6b) in 76.8% yield.     

(2S,3R)-1-二甲氨基-3-(3-甲氧基苯基)-2-甲基戊-3-醇的合成工艺研究

目的 对(2S,3R)- 1-二甲氨基-3-(3-甲氧基苯基)-2-甲基戊-3-醇合成工艺进行研究.方法 以3-戊酮为起始原料,经Mannich反应、手性拆分、Grignard反应等步骤合成(2S,3R)-1-二甲氨基-3-(3-甲氧基苯基)-2-甲基戊-3-醇,并对化学拆分进行工艺优化.结果 合成(2S,3R)-1...     

Synthesis and antimicrobial activity of urea derivatives of (1S,2S)-2-AMINO-1-(4-nitrophenyl)-1,3-propanediol

A series of urea derivatives were synthesized from (1S,2S)-2-amino-1-(4-nitrophenyl)-1,3-propanediol and their antimicrobial activity was studied. The compounds synthesized here showed the greatest levels of activity against strains of Bacillus cereus, Staphylococcus aureus, and Streptococcus haemolyticus.     

Synthesis and Antifungal Activity Evaluation of 1-(2-Benzyloxy-2-Phenylethyl)-1,2,3-Triazole Miconazole Analogs

Pharmaceutical Chemistry Journal - Aseries of 1-(2-aryloxy-2-phenylethyl)-1,2,3-triazole derivatives (Miconazole analogs) was obtained via copper catalyzed azide-alkyne cycloaddition as the key...     

(2R,4R)-4-甲基-2-哌啶甲酸乙酯的合成工艺改进

目的 优化(2R,4R)-4-甲基-2-哌啶甲酸乙酯的合成工艺.方法 以S-(-)-α-甲基苄胺为原料,与乙醛酸乙酯反应得到[(S)-1-苯乙基亚胺基]乙酸乙酯,与异戊二烯进行环合后,再经不对称氢化和脱保护反应制得(2R,4R)-4-甲基-2-哌啶甲酸乙酯.结果 总收率从17.0％提高至47.6％.结论 本工艺可有效地降低生产成本.